December 6 — 10, 2022 San Antonio, CA

Booth #807
1 Product Theatre Presentation
6 Poster Presentations

SABCS 2022

Tempus is advancing precision medicine through the practical application of artificial intelligence in healthcare.
We are pleased to share our latest scientific and clinical research findings during the San Antonio Breast Cancer Symposium 2022. 

Schedule a meeting with us
Product Theatre Presentation
December 10, 2022
live session
10:00am PST

Exhibitor Hall
Calvin Chao, M.D., Senior Vice President of Medical Affairs, Tempus
Cynthia Ma, M.D., PhD, Professor of Medicine, Washington University in St. Louis, Siteman Cancer Center

Advancing The Standards Of Breast Cancer Care With Comprehensive Somatic Next-Generation Sequencing, Germline Testing, And AI-Driven Data

Learn more about our portfolio of comprehensive sequencing and how we are leveraging data to advance precision oncology.

If you missed the live presentation, the product theatre webinar recording can be found on our website following the SABCS meeting.

Poster Presentations
December 6, 2022
5:00pm – 6:15pm PST
Sarah Sammons; Duke
Ezequiel Renzulli; Tempus

DORA: A Phase II, Multicenter, International, Non-Comparator Study of Olaparib (O) +/- Durvalumab (D) as a Chemotherapy-Free Maintenance Strategy in Platinum Treated Advanced Triple-Negative Breast Cancer (aTNBC)

December 7, 2022
7:00am – 8:15am PST
Ami Shah; Northwestern
Adam Brufsky; UPMC
Calvin Chao; Tempus

The mutational landscape of 1172 patients with hormone receptor-positive, HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors

Recent studies suggest possible differences in outcomes among MBC patients treated with palbociclib, ribociclib, or abemaciclib, but whether differences have a genomic basis is unknown. Tempus’ multimodal real-world dataset analyzed 1172 HR+ HER2- MBC patients who received >6 months of CDK4/6i therapy, with focus on comparing genomic and immune biomarker landscapes from Tempus tissue and liquid biopsy testing following each specific CDK4/6i therapy.

7:00am – 8:15am PST
Cynthia Ma; Washington University
Ron Bose; WUSTL
Sherif El-Refai; Tempus

Gene expression and mutation profiles in HER2-mutated metastatic breast cancer

In comparing the mutational landscapes and gene expressions of HER2-mutated MBC patients to HER2-amplified and HER2-wild type MBC patients, Tempus’ multimodal real-world dataset showed different co-occurring genomic alterations among the three groups, while increased HER2 mRNA expression was noted in both HER2-mut and HER2-amp MBC patients.

9:45am – 11:00am PST
Halla Nimeiri; Tempus
Rotem Ben-Shachar; Tempus

Molecular characterization of HER2-low patients identifies basal-enriched subset with poor clinical outcomes in real-world data

Tempus multimodal real-world data reveals that HER2-low breast cancers are comprised of distinct molecular subtypes. HER2-low patients were clustered according to our HER2 expression signature identifying three distinct molecular clusters. A distinct cluster of predominantly basal-like HER2-low patients had shorter real world PFS than other HER2-low patients (n=57). These data further reveal the utilization of RNA expression to fully characterize clinically relevant subpopulations.

December 8, 2022
7:00am – 8:15am PST
Matthew MacKay; Tempus

Rotem Ben-Shachar; Tempus

Dual ctDNA and tissue sequencing improves detection of actionable variants in patients with breast cancer

Of breast cancer patients sequenced concurrently (samples collected ≤ 30 days apart) with liquid- and tissue-based NGS tests who had actionable genomic findings , 20% had unique findings identified in liquid alone that would have been missed by solid testing, while 29% had unique findings identified in solid tissue (n=93/473 and n=136/473, respectively).

5:00pm – 6:15pm PST
M Rosario Chica-Parrado; UTSW
Ariella Hanker; UTSW
Carlos Arteaga; UTSW
Liz Mauer; Tempus

Genomic Landscape of ER+/HER2- metastatic breast cancer as a function of prior treatment with a CDK4/6 inhibitor

Tempus’ multimodal real-world dataset assessed the landscape of somatic alterations from both tissue and liquid biopsies in 1853 HR+ HER2- MBC patients who either received or did not receive prior CDK4/6i therapy, providing insights into potential mechanisms of resistance following such therapies. Patients with prior CDK4/6i therapy harbored significantly more ESR1 somatic alterations, demonstrated in both solid tissue and liquid biopsies.

Schedule a meeting with us

We'll be in touch shortly.